-
Product Insights
NewATP Binding Cassette Sub Family A Member 1 – Drugs In Development, 2024
The ATP Binding Cassette Sub Family A Member 1 pipeline drugs market research report outlays comprehensive information on the ATP Binding Cassette Sub Family A Member 1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Cardiovascular, Gastrointestinal, Metabolic Disorders, and Genito Urinary System which include indications of Atherosclerosis, Metabolic Dysfunction-Associated Steatohepatitis (MASH), Liver Fibrosis, Type 1 Diabetes...
-
Product Insights
NewATP Binding Cassette Sub Family C Member 8 – Drugs In Development, 2024
The ATP Binding Cassette Sub Family C Member 8 pipeline drugs market research report outlays comprehensive information on the ATP Binding Cassette Sub Family C Member 8 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Metabolic Disorders, and Central Nervous System which include indications of Type 2 Diabetes, Gestational Diabetes, and Central Nerve Injury. It also reviews...
-
Product Insights
NewATP Binding Cassette Sub Family G Member 2 – Drugs In Development, 2024
The ATP Binding Cassette Sub Family G Member 2 pipeline drugs market research report outlays comprehensive information on the ATP Binding Cassette Sub Family G Member 2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology which include indications of Unspecified Cancer, and Triple-Negative Breast Cancer (TNBC). It also reviews key players involved in ATP Binding Cassette...
-
Product Insights
NewEukaryotic Peptide Chain Release Factor GTP Binding Subunit ERF3A – Drugs In Development, 2024
The Eukaryotic Peptide Chain Release Factor GTP Binding Subunit ERF3A pipeline drugs market research report outlays comprehensive information on the Eukaryotic Peptide Chain Release Factor GTP Binding Subunit ERF3A targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology which include indications of Unspecified Cancer, and Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia). It also reviews key players...
-
Product Insights
Likelihood of Approval Analysis for Hormone Sensitive Breast Cancer
Overview How likely is it that the drugs in Hormone Sensitive Breast Cancer will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Hormone Sensitive Breast Cancer Overview Estrogen and progesterone promote the...
-
Product Insights
Likelihood of Approval Analysis for Drug Toxicity
Overview How likely is it that the drugs in Drug Toxicity will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Drug Toxicity Overview Drug toxicity' can be defined as a diverse array...
-
Product Insights
Likelihood of Approval Analysis for Acquired (Autoimmune) Hemolytic Anemia
Overview How likely is it that the drugs in Acquired (Autoimmune) Hemolytic Anemia will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Acquired (Autoimmune) Hemolytic Anemia Overview Acquired autoimmune hemolytic anemia (AIHA)...
-
Product Insights
Likelihood of Approval Analysis for Type I Hypersensitivity
Overview How likely is it that the drugs in Type I Hypersensitivity will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Type I Hypersensitivity Overview Type 1 hypersensitivity is a type of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ENT-001 in Ulcerative Colitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ENT-001 in Ulcerative Colitis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ENT-001 in Ulcerative Colitis Drug Details: ENT-001 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ENT-001 in Type 1 Diabetes (Juvenile Diabetes)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ENT-001 in Type 1 Diabetes (Juvenile Diabetes) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ENT-001 in Type 1 Diabetes (Juvenile Diabetes) Drug Details:...